Merck & Company, Inc. vs Arcus Biosciences, Inc. — Stock Comparison
Q·Score Breakdown
6.7
Neutral
Overall
5.7
Neutral
Quality
Health
Growth
Valuation
Sentiment
MRK
Forward P/E of 11.5× is low relative to sector peers.
RCUS
Clean balance sheet with low leverage (0.3× debt-to-equity).
⚠ currently unprofitable (-143% margin).
Analyst Consensus
BUY
Target $129.74 (+15.7%)
27 analysts
BUY
Target $34.00 (+32.4%)
10 analysts
Fundamentals
MRK
RCUS
31.5×
Trailing P/E
—
11.5×
Forward P/E
-7.3×
13.6%
Profit Margin
-142.9%
76.6%
Gross Margin
-111.7%
—
ROE
-63.3%
4.9%
Revenue Growth
26.9%
—
Earnings Growth
—
0.28
Beta
0.86
—
Price / Book
—
$277.0B
Market Cap
$3.2B
$73 – $125
52-Week Range
$7 – $29
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →